Faron Pharmaceuticals Oy (LON:FARN) Stock Price Down 13.4% – Should You Sell?

Faron Pharmaceuticals Oy (LON:FARN)’s share price fell 13.4% during trading on Friday . The stock traded as low as GBX 40 and last traded at GBX 42.46. 169,430 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 162,237 shares. The stock had previously closed at GBX 49.

Faron Pharmaceuticals Oy Trading Down 13.3%

The stock has a market capitalization of £53.50 million, a PE ratio of -1.93 and a beta of 1.18. The firm has a 50 day moving average price of GBX 63.79 and a 200 day moving average price of GBX 140.55. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35.

Insider Activity at Faron Pharmaceuticals Oy

In related news, insider Jurriaan Dekkers sold 4,000 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. Insiders own 3.94% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.